Cowen Cuts Watson Pharma (WPI) to Neutral
Tweet
Share
E-mailGet Alerts WPI Hot Sheet
Price: $85.73 --0%
Rating Summary:
13 Buy, 4 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 18 | New: 20
Rating Summary:
13 Buy, 4 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 18 | New: 20
Join SI Premium – FREE
Cowen downgraded shares of Watson Pharmaceuticals (NYSE: WPI) from Outperform to Neutral Tuesday afternoon.
The call follows preliminary FY11 results and FY12 guidance from Watson this morning. The company also announced an agreement to acquire Ascent Pharmahealth in Australia.
The stock is down nearly 2 percent at last check.
For an analyst ratings summary and ratings history on Watson Pharmaceuticals click here. For more ratings news on Watson Pharmaceuticals click here.
The call follows preliminary FY11 results and FY12 guidance from Watson this morning. The company also announced an agreement to acquire Ascent Pharmahealth in Australia.
The stock is down nearly 2 percent at last check.
For an analyst ratings summary and ratings history on Watson Pharmaceuticals click here. For more ratings news on Watson Pharmaceuticals click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- William Blair Downgrades Enovix Corporation (ENVX) to Market Perform
- Johnson Rice Downgrades Expand Energy (EXE) to Accumulate
- Seaport Global Securities Downgrades JetBlue Airways (JBLU) to Neutral
Create E-mail Alert Related Categories
DowngradesRelated Entities
Cowen & CoSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
